A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1) (NCT04811560)
A Phase 1/2, First-in-Human Study of the Menin-KMT2A (MLL1) Inhibitor Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) of bleximenib in phase 1 Part 1 (Dose Escalation) and to determine the safety and tolerability at RP2D in Phase 1 Part 2 (Dose expansion). The purpose of the Phase 2 part of the study is to evaluate the efficacy of bleximenib at the RP2D.
Who can join: Review the eligibility criteria below.
Location: City of Hope — Duarte, California
Age range: 2 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (102 Sites)
Showing the first 25 of 102 sites.
- City of Hope — Duarte, California
- University of California Irvine Medical Center — Orange, California
- University of California San Francisco — San Francisco, California
- UCSF Benioff Children's Hospital — San Francisco, California
- University of Chicago — Chicago, Illinois
- St Francis Hospital & Health Centers Indiana Blood and Marrow Transplantation — Indianapolis, Indiana
- Norton Cancer Institute — Louisville, Kentucky
- Massachusetts General Hospital — Boston, Massachusetts
- Dana Farber Cancer Institute — Boston, Massachusetts
- Karmanos Cancer Institute — Detroit, Michigan
- Start Midwest — Grand Rapids, Michigan
- University of New Mexico — Albuquerque, New Mexico
- Roswell Park Comprehensive Cancer Center — Buffalo, New York
- NYU Langone Medical Center — New York, New York
- Montefiore Medical Center — The Bronx, New York
- Oregon Health And Science University — Portland, Oregon
- Fox Chase Cancer Center — Philadelphia, Pennsylvania
- Maine Health — Providence, Rhode Island
- University of Tennessee Medical Center — Knoxville, Tennessee
- Baylor University Medical Center — Dallas, Texas
- Houston Methodist Hospital — Houston, Texas
- MD Anderson — Houston, Texas
- San Antonio Methodist TX Transplant Physicians Group — San Antonio, Texas
- Virginia Commonwealth University — Richmond, Virginia
- Swedish Cancer Institute — Seattle, Washington
📞 Contact the Study Coordinator
Phone: (844) 434-4210
Email: Participate-In-This-Study1@its.jnj.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Acute Leukemia
- Cytogenetic Studies in Acute Leukemia and Multiple Myeloma — La Jolla, California
- ATG Plus PTCy vs ATG for CGVHD Prophylaxis — Darlinghurst, New South Wales
- Cancer Stem Cells in Acute Leukemia — Fargo, North Dakota
- A High Intensity Electronic Health Intervention for the Reduction of Learning Disparities in Childhood Cancer Survivors — Duarte, California
- Prevention of Hospital Acquired Deconditioning in Hospitalized Acute Leukemia Patients — Manhasset, New York
- A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies — Duarte, California
Explore by condition: All Acute Leukemia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.